Compare AbbVie Inc (ABBV) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Vanguard High Dividend Yield ETF — how do they compare? AbbVie Inc trades at $253.56 (market cap $449.91B), while Vanguard High Dividend Yield ETF trades at $160.01. The key difference: AbbVie Inc pays a 2.72% dividend while Vanguard High Dividend Yield ETF pays none. Which is the better fit depends on your goals.
| ABBV | VYM | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | — |
52-Week High | $261.07 | $161.17 |
52-Week Low | $184.85 | $132.90 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
VYM trades at $160.14, up 0.41% with a bullish technical outlook supported by moving averages. The ETF focuses on high dividend yield stocks, offering investors steady income through quarterly distributions. Recent news highlights strong investor interest in dividend ETFs for retirement income, with VYM being frequently compared to peers like VIG and SCHD for its diversification and low 0.04% expense ratio.
VYM presents a compelling income-focused investment with stable technical momentum, though RSI levels suggest potential near-term consolidation. The fund's broad diversification across 618 stocks provides resilience, but investors should monitor sector concentration risks and interest rate sensitivity that could impact dividend sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
